Literature DB >> 19689766

End-of-life care for older adults with dementia living in group homes in Japan.

Sayuri Kobayashi1, Noriko Yamamoto-Mitani, Satoko Nagata, Sachiyo Murashima.   

Abstract

AIM: The aim of this study was to elucidate the components of end-of-life care provided to older adults with dementia who live in group homes (GHs) in Japan.
INTRODUCTION: The number of GHs in Japan is rapidly increasing. Although GHs were originally not established to care for elderly people with advanced-stage dementia, many residents remain in the GH even after their stage of dementia advances; thus, end-of-life care is required.
METHODS: Interviews were conducted with seven GH administrators on their experience in providing end-of-life care to their residents. The constant comparative approach was used for data collection and analysis.
FINDINGS: Four themes emerged as essential components of end-of-life care in the GH setting: (i) maintaining a familiar lifestyle; (ii) minimizing physical and mental discomfort; (iii) proactively utilizing desirable medical care; and (iv) collaborating with family members.
CONCLUSION: The combination of the four components seems to be a unique characteristic of end-of-life care in GHs in Japan. These findings may be used to establish a framework for end-of-life care at GHs.

Entities:  

Mesh:

Year:  2008        PMID: 19689766     DOI: 10.1111/j.1742-7924.2008.00097.x

Source DB:  PubMed          Journal:  Jpn J Nurs Sci        ISSN: 1742-7924            Impact factor:   1.418


  2 in total

1.  The vital prognosis of elderly adults living in a group home in their mid-eighties.

Authors:  Kikue Todoroki; Yoshimori Ikeya; Sayato Fukui; Chiharu Tanaka; Kaori Sekine; Ryoko Imazeki; Toru Shizuma; Naoto Fukuyama; Hidezo Mori
Journal:  J Physiol Sci       Date:  2016-09-21       Impact factor: 2.781

2.  Defining end of life in dementia: A systematic review.

Authors:  Bria Browne; Nuriye Kupeli; Kirsten J Moore; Elizabeth L Sampson; Nathan Davies
Journal:  Palliat Med       Date:  2021-06-17       Impact factor: 4.762

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.